ACXIT Capital Partners advised Zur Rose Group on the successful placement of CHF 175M Convertible Bonds - ACXIT Capital Partners
UBS: 1Q21 Net Profit of USD 1.8bn, 18.2% Return on CET1 Capital | Business Wire
Christoph Herrmann - Director Investor Relations - Zur Rose Group AG | XING
Zur Rose Group successfully concluded acquisition of the e-commerce and diabetes activities of Apotal Group
Investor Relations | Schindler Group
Financial News | Beiersdorf
Goldman Sachs 2020 Annual Report
Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term growth opportunity ? | value and opportunity
The NAGA Group AG: Products, Stock, News
Zur Rose Group – Marke
Our 2020 in review | UBS Global
Olaf Heinrich, Head Germany, verlässt die Zur Rose-Gruppe; sein Nachfolger wird Walter Hess, Head Switzerland
Corporate Governance
Olaf Heinrich, Head Germany, is leaving the Zur Rose Group; his successor will be Walter Hess, Head Switzerland
Zur Rose Group - Pharmaceuticals - Overview, Competitors, and Employees | Apollo.io
Zur Rose Ecosystem - Annual Report 2018 | Zur Rose Group AG
Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St
Zur Rose Group AG - Crunchbase Company Profile & Funding
Financials - Annual Report 2020 | Zur Rose Group AG
Christoph Herrmann – Head of Investor Relations – Zur Rose Group | LinkedIn
Zur Rose Group AG
Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St
FY 2021 IFRS RESULTS - EuroChem Group
